title: Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis.
authors.forename: G F
authors.initials: GF
authors.lastname: Ferraccioli
authors.forename: E
authors.initials: E
authors.lastname: Bartoli
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000627:therapeutic use; D015262:Xenobiotics
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D015262:Xenobiotics; D016572:Cyclosporine; D020123:Sirolimus; D008727:Methotrexate